A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Lumacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Have an A455E-CFTR Mutation
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 08 Nov 2017 Status changed from active, no longer recruiting to completed.
- 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2017 New trial record